The CXCL13 chemokine serves as a potential biomarker to diagnose systemic lupus erythaematosus with disease activity
| Autor: | Xuelian Wang, Qinggui Chen, Yan-Li Zeng, Jiajia Wang, Yiqiang Lin, Qinghe Huang, Yun Xiao, Yan Zhang, Longcan Jiang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Chemokine Enzyme-Linked Immunosorbent Assay General Biochemistry Genetics and Molecular Biology Arthritis Rheumatoid Disease activity 03 medical and health sciences 0302 clinical medicine immune system diseases Internal medicine Humans Lupus Erythematosus Systemic Medicine CXCL13 Risk factor skin and connective tissue diseases Hematology biology business.industry Systemic lupus Curve analysis General Medicine Serum samples medicine.disease Chemokine CXCL13 Lupus Nephritis 030104 developmental biology 030220 oncology & carcinogenesis Rheumatoid arthritis Potential biomarkers Immunology biology.protein business Biomarkers |
| DOI: | 10.22541/au.160405570.08073821/v1 |
| Popis: | The aim of our study was to assess the regulatory response of the chemokine CXCL13 in the serum of systemic lupus erythematosus (SLE) patients with disease activity and to evaluate its influence on the inflammatory process in SLE. Serum samples from 97 SLE patients, 49 non-SLE patients (23 patients with other autoimmune diseases and 26 patients with rheumatoid arthritis) and 50 healthy controls were analyzed for the concentration of CXCL13 using ELISA. The results indicated that the serum levels of CXCL13 were significantly higher in SLE patients than in non-SLE patients and healthy controls (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|